Name: MINERALYS THERAPEUTICS INC (MLYS) Stock
Brand: MINERALYS THERAPEUTICS INC
Rating: 7 (3 reviews)

MLYS Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Chartmill

MINERALYS THERAPEUTICS INC (NASDAQ:MLYS) Beats Q3 2025 EPS Estimates and Advances Key Drug Candidate

3 days ago - By: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

4 days ago - By: Benzinga - Mentions: OGN TACT IMDX QRHC ...

Earnings Scheduled For November 10, 2025

6 days ago - By: Mineralys Therapeutics, Inc.

Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025

6 days ago - By: Benzinga

Uncovering Potential: Mineralys Therapeutics's Earnings Preview

2 months ago - By: The Motley Fool - Mentions: NKTR

These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?

2 months ago - By: The Motley Fool - Mentions: COCO SATS MDY IWM ...

It's a Small World: 3 Stocks Leading the Sudden Rebound in Small Caps

2 months ago - By: Zacks Investment Research

What Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now?

2 months ago - By: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need

2 months ago - By: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

2 months ago - By: Yahoo Finance

Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak

2 months ago - By: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

2 months ago - By: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

3 months ago - By: Investor's Business Daily - Mentions: GS AZN

AstraZeneca's $80 Billion Ambition Just Got A Big Infusion With New Hypertension Results

3 months ago - By: Zacks Investment Research

Wall Street Analysts Believe Mineralys Therapeutics, Inc. (MLYS) Could Rally 149.66%: Here's is How to Trade

3 months ago - By: Mineralys Therapeutics, Inc.

Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025

5 months ago - By: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat

5 months ago - By: Bloomberg

MINERALYS THERAPEUTICS INC (MLYS) Stock News

MLYS Latest News, Press Relases and Analysis

MINERALYS THERAPEUTICS INC (NASDAQ:MLYS) Beats Q3 2025 EPS Estimates and Advances Key Drug Candidate

Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Earnings Scheduled For November 10, 2025

Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025

Uncovering Potential: Mineralys Therapeutics's Earnings Preview

These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?

It's a Small World: 3 Stocks Leading the Sudden Rebound in Small Caps

What Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now?

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need

Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

AstraZeneca's $80 Billion Ambition Just Got A Big Infusion With New Hypertension Results

Wall Street Analysts Believe Mineralys Therapeutics, Inc. (MLYS) Could Rally 149.66%: Here's is How to Trade

Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025

Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat

Mineralys’ Drug Significantly Cut Blood Pressure in Key Study